Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coloplast ASCLPBF 72 Debt-to-EBITDA is 2.64 as of Mar. 2026, which is 676% above its 10-year median of 0.34. GuruFocus rates CLPBF with a GF Score™ of 72/100 and a GF Value™ of $126.28 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 467 Medical Devices & Instruments companies, Coloplast AS ranks worse than 66.38% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Coloplast AS's Debt-to-EBITDA or its related term are showing as below:
CLPBF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.05 Med: 0.34 Max: 2.71
Current: 2.71
During the past 13 years, the highest Debt-to-EBITDA Ratio of Coloplast AS was 2.71. The lowest was 0.05. And the median was 0.34.
CLPBF's Debt-to-EBITDA is ranked worse than 66.38% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.57
vs CLPBF: 2.71
Coloplast AS (OTCPK:CLPBF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Coloplast AS Debt-to-EBITDA Related Terms
Coloplast AS Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Coloplast AS's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLPBF vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Coloplast AS's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coloplast AS Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Coloplast AS's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Coloplast AS (CLPBF) has a Debt-to-EBITDA of 2.64 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Coloplast AS. This is 676% above median its historical median of 0.34. Over the past decade, Coloplast AS's Debt-to-EBITDA has ranged from 0.05 to 2.71. According to the industry distribution chart, Coloplast AS ranks #310 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 66.4%.
Is Coloplast AS's Debt-to-EBITDA too high?
Coloplast AS's current Debt-to-EBITDA of 2.64 is 676% above median its 10-year median of 0.34. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 2.71. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.57. Coloplast AS's value of 2.64 is 68.2% above this industry median. Based on the distribution chart, Coloplast AS ranks #310 out of 467 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Coloplast AS has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Coloplast AS ranks #310 out of 467 companies for Debt-to-EBITDA. This places Coloplast AS in the lower half of its industry. The industry median Debt-to-EBITDA is 1.57. Coloplast AS's value of 2.64 is 68.2% above this benchmark. Historically, Coloplast AS's own Debt-to-EBITDA has ranged from 0.05 to 2.71 over the past decade. While the company's 10-year median is 0.34 vs. the industry median of 1.57, Coloplast AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.57, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coloplast AS's current Debt-to-EBITDA of 2.64 is 68.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Coloplast AS. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coloplast AS's current Debt-to-EBITDA is 2.64, which is 676% above median its own 10-year median of 0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $126.28, compared to a current price of $60.06 — trading 52.4% below its estimated fair value. The current Debt-to-EBITDA is 2.64, which is 676% above median its 10-year median of 0.34 and 68.2% above the Medical Devices & Instruments industry median of 1.57. Coloplast AS's overall GF Score™ is 72/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Coloplast AS (CLPBF), the current Debt-to-EBITDA is 2.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBF) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $60.06 is trading 52.4% below its estimated GF Value™ of $126.28.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBF:
Debt-to-EBITDA: 2.64 (676% above median its 10-year median of 0.34)
GF Value™: $126.28 vs. price of $60.06 (52.4% below fair value)
Industry Position: 68.2% above the Medical Devices & Instruments median (#310 of 467)
No single metric tells the full story. See the CLPBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
72GF Score
Get the complete analysis for CLPBF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBF has been successfully added to your 
